Terns Pharma Files SC14D9C for Third-Party Tender Offer

TL;DR

**Terns Pharma is the target of a tender offer, expect potential stock price movement.**

AI Summary

This SC14D9C filing from Terns Pharmaceuticals, Inc. on March 25, 2026, indicates a written communication related to a third-party tender offer. While the filing itself doesn't detail the offer, it signals that Terns Pharmaceuticals is the subject of a potential acquisition or significant share purchase by another entity. This matters to shareholders because tender offers often involve a premium over the current stock price, which could lead to a quick profit, but also means the company might be taken private or its ownership structure significantly altered.

Why It Matters

This filing signals that Terns Pharmaceuticals is likely the target of a tender offer, which could result in shareholders selling their stock at a premium or the company undergoing a significant change in control.

Risk Assessment

Risk Level: medium — The risk is medium because while tender offers can provide a premium, the offer might not materialize, or the terms could be less favorable than anticipated, leading to uncertainty.

Analyst Insight

A smart investor would monitor Terns Pharmaceuticals, Inc. closely for further announcements regarding the tender offer, as the terms could significantly impact share value. Consider holding existing shares if the offer is expected to be at a premium, but be prepared for potential price fluctuations.

Key Numbers

• 0001831363 — CIK (Unique identifier for Terns Pharmaceuticals, Inc.)
• 2026-03-25 — Filing Date (Date the SC14D9C was filed and accepted by the SEC.)
• 18250 — Size (bytes) (Size of the primary SC14D9C document (d92692dsc14d9c.htm).)
• 005-92116 — File No. (SEC file number for Terns Pharmaceuticals, Inc.)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations.)

Key Players & Entities

• Terns Pharmaceuticals, Inc. (company) — the subject and filer of the SC14D9C
• 0001831363 (company) — CIK for Terns Pharmaceuticals, Inc.
• 0001193125-26-122823 (person) — SEC Accession No. for the filing
• 2026-03-25 (person) — Filing Date and Accepted Date
• 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 (person) — Mailing and Business Address for Terns Pharmaceuticals, Inc.

Forward-Looking Statements

• The stock price of Terns Pharmaceuticals, Inc. will experience increased volatility. (Terns Pharmaceuticals, Inc.) — high confidence, target: 2026-04-25
• Further details regarding the third-party tender offer will be disclosed in subsequent filings. (Terns Pharmaceuticals, Inc.) — high confidence, target: 2026-05-25

FAQ

Key Financial Figures

• $0.0001 — ng Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securiti

Filing Documents

• d92692dsc14d9c.htm (SC14D9C) — 18KB
• d92692dex991.htm (EX-99.1) — 12KB
• d92692dex992.htm (EX-99.2) — 11KB
• 0001193125-26-122823.txt ( ) — 42KB

Forward-Looking Statements

Forward-Looking Statements This Schedule 14D-9 filing contains forward-looking statements about the Company within the meaning of the federal securities laws, including regarding the potential sale of the Company. All statements other than statements of historical facts contained in this filing are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including (a) risks related to the timing of the Offer, the Merger and the other Transactions or that the Offer, the Merger and the other Transactions may not be completed at all, (b) whether sufficient stockholders of Terns will tender their Shares in the Offer, (c) the risk that competing offers or acquisition proposals will be made, (d) the possibility that various conditions to the consummation of the Offer or the Merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the

View Full Filing

View this SC14D9C filing on SEC EDGAR